GIP and hydrops fetalis: The SUMMIT trial studied the effect of tirzepatide (up to 15 mg s.c. once per week), a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, in 731 patients with a BMI ≥30 kg/m2 and HFpEF.53 After 104 weeks, tirzepatide reduced the composite of adjudicated CV death or a worsening HF event (HR 0.62; 0.41–0.95; P = 0.026).